Literature DB >> 18071867

Treatment-related ureteral cancer following stage II testicular seminoma.

Kosuke Mizutani1, Hidetoshi Ehara, Shigeaki Yokoi, Nguyen B Phuoc, Takashi Deguchi, Yoshinobu Hirose.   

Abstract

We report two cases of left ureteral carcinoma that may have been related to prior radiotherapy and anticancer chemotherapy for stage II testicular seminoma. Both patients had undergone radiotherapy (60 Gy) and cisplatin-based chemotherapy, one 17 years before the present presentation and the other 24 years earlier. They underwent retroperitoneoscopy-assisted left nephroureterectomy under a diagnosis of left upper ureteral cancer, established by means of ureteroscopy and brush biopsy. The urologic and radiologic outcomes have been satisfactory after more than 2 years of follow-up. Recently, some investigators have reported that testicular cancer survivors are at significantly increased risk of solid tumors for at least 35 years after treatment. Young patients may have a high risk of cancer when they reach an advanced age.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18071867     DOI: 10.1007/s10147-007-0679-5

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  17 in total

1.  Radiation therapy-associated invasive bladder tumors.

Authors:  A Sella; F H Dexeus; C Chong; J Y Ro; C J Logothetis
Journal:  Urology       Date:  1989-03       Impact factor: 2.649

2.  Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up.

Authors:  Stanley L Liauw; John E Sylvester; Christopher G Morris; John C Blasko; Peter D Grimm
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-08-02       Impact factor: 7.038

3.  Second non-germ cell malignancies in patients treated for stage I-II testicular seminoma.

Authors:  J M Bachaud; F Berthier; M Soulié; B Malavaud; P Plante; P Rischmann; C Chevreau; N Daly-Schveitzer; P Grosclaude
Journal:  Radiother Oncol       Date:  1999-02       Impact factor: 6.280

4.  Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer.

Authors:  Kristin Chrouser; Bradley Leibovich; Erik Bergstralh; Horst Zincke; Michael Blute
Journal:  J Urol       Date:  2005-07       Impact factor: 7.450

5.  Secondary malignancy among seminoma patients treated with adjuvant radiation therapy.

Authors:  C K Chao; P P Lai; J M Michalski; C A Perez
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-11-01       Impact factor: 7.038

6.  Radiation dose and second cancer risk in patients treated for cancer of the cervix.

Authors:  J D Boice; G Engholm; R A Kleinerman; M Blettner; M Stovall; H Lisco; W C Moloney; D F Austin; A Bosch; D L Cookfair; E T Krementz; H B Latourette; J A Merrill; L J Peters; M D Schulz; H H Storm; E Bjorkholm; F Pettersson; C M Janine Bell; M P Coleman; P Fraser; F E Neal; P Prior; N W Choi; T G Hislop; M Koch; N Kreiger; D Robb; D Robson; D H Thomson; H Lochmuller; D von Fournier; R Frischkorn; K E Kjørstad; A Rimpela; M H Pejovic; V P Kirn; H Stankusova; F Berrino; K Sigurdsson; G B Hutchison; B MacMahon
Journal:  Radiat Res       Date:  1988-10       Impact factor: 2.841

7.  Mortality after cure of testicular seminoma.

Authors:  Gunar K Zagars; Matthew T Ballo; Andrew K Lee; Sara S Strom
Journal:  J Clin Oncol       Date:  2004-01-15       Impact factor: 44.544

8.  Cardiovascular disease as a long-term complication of treatment for testicular cancer.

Authors:  R A Huddart; A Norman; M Shahidi; A Horwich; D Coward; J Nicholls; D P Dearnaley
Journal:  J Clin Oncol       Date:  2003-04-15       Impact factor: 44.544

9.  Second primary bladder cancer following pelvic irradiation for other malignancies.

Authors:  R Ravi
Journal:  J Surg Oncol       Date:  1993-09       Impact factor: 3.454

10.  Seminoma of the testis: long-term beneficial and deleterious results of radiation.

Authors:  G E Hanks; T Peters; J Owen
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.